

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
Date of first issue: 12/19/2019

SECTION 1. IDENTIFICATION

Product name : Levamisole / Oxyclozanide Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product


Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Reproductive toxicity : Category 2
Specific target organ toxicity : Category 2 (Central nervous system)
- single exposure (Oral)
Specific target organ toxicity : Category 2 (Brain, Liver)
- repeated exposure
Specific target organ toxicity : Category 2 (Blood, Testis)
- repeated exposure (Oral)

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.
H373 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
 Date of first issue: 12/19/2019

P260 Do not breathe mist or vapors.
 P264 Wash skin thoroughly after handling.
 P270 Do not eat, drink or smoke when using this product.
 P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P308 + P311 IF exposed or concerned: Call a doctor.
 P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Kaolin	1332-58-7	6
Oxyclozanide	2277-92-1	3
Levamisole hydrochloride	16595-80-5	1.5
Citric acid	77-92-9	1.37

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
 Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
 Remove contaminated clothing and shoes.
 Get medical attention.
 Wash clothing before reuse.
 Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
 Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
 Get medical attention.
 Rinse mouth thoroughly with water.
 Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and : Suspected of damaging the unborn child.
 May cause damage to organs if swallowed.

Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
1.7	10/01/2022	5360104-00008	Date of first issue: 12/19/2019

delayed : May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Silicon oxides
Metal oxides
Chlorine compounds
Nitrogen oxides (NO_x)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
 Date of first issue: 12/19/2019

employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe mist or vapors.
 Do not swallow.
 Avoid contact with eyes.
 Avoid prolonged or repeated contact with skin.
 Wash skin thoroughly after handling.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Do not eat, drink or smoke when using this product.
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Store locked up.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents
 Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Kaolin	1332-58-7	TWA (Respirable particulate matter)	2 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Oxyclozanide	2277-92-1	TWA	0.4 mg/m ³ (OEB 2)	Internal
		Wipe limit	400 mg/100 cm ²	Internal
Levamisole hydrochloride	16595-80-5	TWA	20 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	200 µg/100 cm ²	Internal

Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
1.7	10/01/2022	5360104-00008	Date of first issue: 12/19/2019

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
Date of first issue: 12/19/2019

Appearance : liquid

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
Date of first issue: 12/19/2019

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:**Kaolin:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 2.07 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Oxyclozanide:

Acute oral toxicity : LD50 (Rat): 3,519 mg/kg
Target Organs: Central nervous system

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg
Application Route: Intravenous

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
Date of first issue: 12/19/2019

Levamisole hydrochloride:

Acute oral toxicity : LD50 (Rat): 180 mg/kg
LD50 (Mouse): 223 mg/kg
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Kaolin:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Oxyclozanide:

Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Remarks : No data available

Citric acid:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Kaolin:**

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
Date of first issue: 12/19/2019

Oxyclozanide:

Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Remarks : No data available

Citric acid:

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Oxyclozanide:**

Routes of exposure : Dermal
Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:**Oxyclozanide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive

Test Type: Mouse Lymphoma
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat

Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
1.7	10/01/2022	5360104-00008	Date of first issue: 12/19/2019

Cell type: Liver cells
 Application Route: Oral
 Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Levamisole hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: Chromosome aberration test in vitro
 Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: in vitro micronucleus test
 Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
 Species: Rat
 Application Route: Ingestion
 Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Oxyclozanide:

Remarks : Not classified due to lack of data.

Levamisole hydrochloride:

Species : Mouse
 Application Route : Oral
 Exposure time : 2 Years
 NOAEL : 80 mg/kg body weight
 Remarks : No significant adverse effects were reported

Species : Rat
 Application Route : Oral
 Exposure time : 2 Years
 NOAEL : 40 mg/kg body weight
 Remarks : No significant adverse effects were reported

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
1.7	10/01/2022	5360104-00008	Date of first issue: 12/19/2019

identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Oxyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
 Species: Rat, male and female
 Application Route: Oral
 General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight
 Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
 Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study
 Species: Rat
 Application Route: Oral
 General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight
 Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
 Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study
 Species: Rat
 Application Route: Oral
 Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight
 Result: No fetotoxicity., No teratogenic effects.

Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Oral
 General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight
 Result: No fetotoxicity., No teratogenic effects., No effects on fertility.

Effects on fetal development : Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 200 mg/kg body weight
 Result: No fetotoxicity., No teratogenic effects.

Test Type: Development
 Species: Rat
 Application Route: Oral
 General Toxicity Maternal: LOAEL: 100 mg/kg body weight
 Result: No fetotoxicity., No teratogenic effects.

Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
1.7	10/01/2022	5360104-00008	Date of first issue: 12/19/2019

Test Type: Development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: NOAEL: 32 mg/kg body weight
 Result: Fetotoxicity., Skeletal malformations.

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

Levamisole hydrochloride:

Effects on fertility : Test Type: Three-generation reproduction toxicity study
 Species: Rat
 Application Route: Oral
 Result: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 20 mg/kg body weight
 Result: Fetotoxicity.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: LOAEL: 40 mg/kg body weight
 Result: Fetotoxicity.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Citric acid:

Effects on fetal development : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

STOT-single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:

Oxyclozanide:

Routes of exposure : Oral
 Target Organs : Central nervous system
 Assessment : May cause damage to organs.

Citric acid:

Assessment : May cause respiratory irritation.

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
 Date of first issue: 12/19/2019

STOT-repeated exposure

May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.
 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

Components:

Oxyclozanide:

Target Organs : Brain, Liver
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Levamisole hydrochloride:

Target Organs : Blood, Testis
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Oxyclozanide:

Species : Rat
 NOAEL : 9 mg/kg
 LOAEL : 44.5 mg/kg
 Application Route : Oral
 Exposure time : 3 Months
 Target Organs : Brain, Liver, spleen, Adrenal gland
 Symptoms : Liver effects

Species : Dog
 NOAEL : 5 mg/kg
 LOAEL : 25 mg/kg
 Application Route : Oral
 Exposure time : 3 Months
 Target Organs : Brain, Liver
 Symptoms : blood effects, alteration in liver enzymes

Levamisole hydrochloride:

Species : Rat
 NOAEL : 2.5 mg/kg
 Application Route : Oral
 Exposure time : 18 Months
 Target Organs : Testis

Species : Dog
 LOAEL : 20 mg/kg
 Application Route : Oral
 Exposure time : 18 Months
 Target Organs : Blood

Species : Dog
 LOAEL : 40 mg/kg

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
Date of first issue: 12/19/2019

Application Route : Oral
Exposure time : 3 Months

Citric acid:

Species : Rat
NOAEL : 4,000 mg/kg
LOAEL : 8,000 mg/kg
Application Route : Ingestion
Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

Components:**Oxyclozanide:**

Not applicable

Experience with human exposure**Components:****Oxyclozanide:**

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

Levamisole hydrochloride:

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Kaolin:**

Toxicity to fish (Chronic toxicity) : NOELR (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 30 d

Oxyclozanide:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Levamisole hydrochloride:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l
Exposure time: 48 h

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
Date of first issue: 12/19/2019

Method: OECD Test Guideline 202

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l
Exposure time: 24 h

Persistence and degradability**Components:****Oxyclozanide:**

Stability in water : Hydrolysis: 50 %(156 d)
Method: OECD Test Guideline 111

Citric acid:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential**Components:****Oxyclozanide:**

Partition coefficient: n-octanol/water : log Pow: 3.99
pH: 7
Method: OECD Test Guideline 107

Citric acid:

Partition coefficient: n-octanol/water : log Pow: -1.72

Mobility in soil**Components:****Oxyclozanide:**

Distribution among environmental compartments : log Koc: 4.83
Method: OECD Test Guideline 106

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
1.7	10/01/2022	5360104-00008	Date of first issue: 12/19/2019

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)
 Class : 9
 Packing group : III
 Labels : 9

IATA-DGR

UN/ID No. : UN 3082
 Proper shipping name : Environmentally hazardous substance, liquid, n.o.s. (Oxyclozanide)
 Class : 9
 Packing group : III
 Labels : Miscellaneous
 Packing instruction (cargo aircraft) : 964
 Packing instruction (passenger aircraft) : 964
 Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Oxyclozanide)
 Class : 9
 Packing group : III
 Labels : 9
 EmS Code : F-A, S-F
 Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number : UN 3082
 Proper shipping name : Environmentally hazardous substance, liquid, n.o.s. (Oxyclozanide)
 Class : 9
 Packing group : III
 Labels : CLASS 9
 ERG Code : 171
 Marine pollutant : yes(Oxyclozanide)
 Remarks : Above applies only to containers over 119 gallons or 450 liters.

Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
1.7	10/01/2022	5360104-00008	Date of first issue: 12/19/2019

Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Water	7732-18-5
Kaolin	1332-58-7
Oxyclozanide	2277-92-1

California Permissible Exposure Limits for Chemical Contaminants

Kaolin	1332-58-7
--------	-----------

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined


SECTION 16. OTHER INFORMATION

Further information

Levamisole / Oxyclozanide Formulation

Version 1.7 Revision Date: 10/01/2022 SDS Number: 5360104-00008 Date of last issue: 04/09/2022
 Date of first issue: 12/19/2019

NFPA 704:



HMIS® IV:

HEALTH	*	3
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative)

Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
1.7	10/01/2022	5360104-00008	Date of first issue: 12/19/2019

tative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 10/01/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8